The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Urological Cancer Therapeutics Drugs Market Research Report 2025

Global Urological Cancer Therapeutics Drugs Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1563702

No of Pages : 98

Ask Your Query

Synopsis

Global Urological Cancer Therapeutics Drugs Market is estimated to reach $48.6 billion by 2025 Says, .Now a days urological cancers became very common worldwide and causing higher mortality rates. Specially in the case of kidney cancers, that illustrates the new therapeutic targets. Urological cancers accounts for approximately 20% of global cancer prevalence. This type of cancer affects the urinary tract of male and female and the male reproductive organs.

The global Urological Cancer Therapeutics Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

North American market for Urological Cancer Therapeutics Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Urological Cancer Therapeutics Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Urological Cancer Therapeutics Drugs in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Urological Cancer Therapeutics Drugs include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation and Dendreon Corporation, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Urological Cancer Therapeutics Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Urological Cancer Therapeutics Drugs.

Report Scope

The Urological Cancer Therapeutics Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Urological Cancer Therapeutics Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Urological Cancer Therapeutics Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company (Partial List)

  • Novartis
  • Pfizer
  • Johnson & Johnson
  • AstraZeneca
  • Astellas
  • Bristol-Myers Squibb
  • Abbott Laboratories
  • Celgene Corporation
  • Dendreon Corporation
  • Ferring Pharmaceuticals
  • GlaxoSmithKline plc
  • Indevus Pharmaceuticals Inc
  • Ipsen
  • Roche Healthcare
  • Sanofi S.A.

Segment by Type

  • Xofigo (radium Ra 223 dichloride)
  • Jevtana (cabazitaxel)
  • Inlyta (axitinib)
  • Votrient (pazopanib hydrochloride)
  • Sutent (sunitinib malate)
  • Zytiga (abiraterone acetate)
  • Xtandi (enzalutamide)
  • Opdivo (nivolumab)
  • Provenge (sipuleucel-T)

Segment by Application

  • Hospital
  • Medical Research Laboratory
  • Others

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Urological Cancer Therapeutics Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Xofigo (radium Ra 223 dichloride)
1.2.3 Jevtana (cabazitaxel)
1.2.4 Inlyta (axitinib)
1.2.5 Votrient (pazopanib hydrochloride)
1.2.6 Sutent (sunitinib malate)
1.2.7 Zytiga (abiraterone acetate)
1.2.8 Xtandi (enzalutamide)
1.2.9 Opdivo (nivolumab)
1.2.10 Provenge (sipuleucel-T)
1.3 Market by Application
1.3.1 Global Urological Cancer Therapeutics Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Medical Research Laboratory
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Urological Cancer Therapeutics Drugs Market Perspective (2019-2030)
2.2 Urological Cancer Therapeutics Drugs Growth Trends by Region
2.2.1 Global Urological Cancer Therapeutics Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Urological Cancer Therapeutics Drugs Historic Market Size by Region (2019-2024)
2.2.3 Urological Cancer Therapeutics Drugs Forecasted Market Size by Region (2025-2030)
2.3 Urological Cancer Therapeutics Drugs Market Dynamics
2.3.1 Urological Cancer Therapeutics Drugs Industry Trends
2.3.2 Urological Cancer Therapeutics Drugs Market Drivers
2.3.3 Urological Cancer Therapeutics Drugs Market Challenges
2.3.4 Urological Cancer Therapeutics Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Urological Cancer Therapeutics Drugs Players by Revenue
3.1.1 Global Top Urological Cancer Therapeutics Drugs Players by Revenue (2019-2024)
3.1.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Urological Cancer Therapeutics Drugs Revenue
3.4 Global Urological Cancer Therapeutics Drugs Market Concentration Ratio
3.4.1 Global Urological Cancer Therapeutics Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Urological Cancer Therapeutics Drugs Revenue in 2023
3.5 Urological Cancer Therapeutics Drugs Key Players Head office and Area Served
3.6 Key Players Urological Cancer Therapeutics Drugs Product Solution and Service
3.7 Date of Enter into Urological Cancer Therapeutics Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Urological Cancer Therapeutics Drugs Breakdown Data by Type
4.1 Global Urological Cancer Therapeutics Drugs Historic Market Size by Type (2019-2024)
4.2 Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Type (2025-2030)
5 Urological Cancer Therapeutics Drugs Breakdown Data by Application
5.1 Global Urological Cancer Therapeutics Drugs Historic Market Size by Application (2019-2024)
5.2 Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Urological Cancer Therapeutics Drugs Market Size (2019-2030)
6.2 North America Urological Cancer Therapeutics Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Urological Cancer Therapeutics Drugs Market Size by Country (2019-2024)
6.4 North America Urological Cancer Therapeutics Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Urological Cancer Therapeutics Drugs Market Size (2019-2030)
7.2 Europe Urological Cancer Therapeutics Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Urological Cancer Therapeutics Drugs Market Size by Country (2019-2024)
7.4 Europe Urological Cancer Therapeutics Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Urological Cancer Therapeutics Drugs Market Size (2019-2030)
8.2 Asia-Pacific Urological Cancer Therapeutics Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Urological Cancer Therapeutics Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Urological Cancer Therapeutics Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Urological Cancer Therapeutics Drugs Market Size (2019-2030)
9.2 Latin America Urological Cancer Therapeutics Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Urological Cancer Therapeutics Drugs Market Size by Country (2019-2024)
9.4 Latin America Urological Cancer Therapeutics Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Urological Cancer Therapeutics Drugs Market Size (2019-2030)
10.2 Middle East & Africa Urological Cancer Therapeutics Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Urological Cancer Therapeutics Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Urological Cancer Therapeutics Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Urological Cancer Therapeutics Drugs Introduction
11.1.4 Novartis Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024)
11.1.5 Novartis Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Urological Cancer Therapeutics Drugs Introduction
11.2.4 Pfizer Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Introduction
11.3.4 Johnson & Johnson Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024)
11.3.5 Johnson & Johnson Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Detail
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Introduction
11.4.4 AstraZeneca Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024)
11.4.5 AstraZeneca Recent Development
11.5 Astellas
11.5.1 Astellas Company Detail
11.5.2 Astellas Business Overview
11.5.3 Astellas Urological Cancer Therapeutics Drugs Introduction
11.5.4 Astellas Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024)
11.5.5 Astellas Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Detail
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Introduction
11.6.4 Bristol-Myers Squibb Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024)
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Abbott Laboratories
11.7.1 Abbott Laboratories Company Detail
11.7.2 Abbott Laboratories Business Overview
11.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Introduction
11.7.4 Abbott Laboratories Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024)
11.7.5 Abbott Laboratories Recent Development
11.8 Celgene Corporation
11.8.1 Celgene Corporation Company Detail
11.8.2 Celgene Corporation Business Overview
11.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Introduction
11.8.4 Celgene Corporation Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024)
11.8.5 Celgene Corporation Recent Development
11.9 Dendreon Corporation
11.9.1 Dendreon Corporation Company Detail
11.9.2 Dendreon Corporation Business Overview
11.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Introduction
11.9.4 Dendreon Corporation Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024)
11.9.5 Dendreon Corporation Recent Development
11.10 Ferring Pharmaceuticals
11.10.1 Ferring Pharmaceuticals Company Detail
11.10.2 Ferring Pharmaceuticals Business Overview
11.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Introduction
11.10.4 Ferring Pharmaceuticals Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024)
11.10.5 Ferring Pharmaceuticals Recent Development
11.11 GlaxoSmithKline plc
11.11.1 GlaxoSmithKline plc Company Detail
11.11.2 GlaxoSmithKline plc Business Overview
11.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Introduction
11.11.4 GlaxoSmithKline plc Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024)
11.11.5 GlaxoSmithKline plc Recent Development
11.12 Indevus Pharmaceuticals Inc
11.12.1 Indevus Pharmaceuticals Inc Company Detail
11.12.2 Indevus Pharmaceuticals Inc Business Overview
11.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Introduction
11.12.4 Indevus Pharmaceuticals Inc Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024)
11.12.5 Indevus Pharmaceuticals Inc Recent Development
11.13 Ipsen
11.13.1 Ipsen Company Detail
11.13.2 Ipsen Business Overview
11.13.3 Ipsen Urological Cancer Therapeutics Drugs Introduction
11.13.4 Ipsen Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024)
11.13.5 Ipsen Recent Development
11.14 Roche Healthcare
11.14.1 Roche Healthcare Company Detail
11.14.2 Roche Healthcare Business Overview
11.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Introduction
11.14.4 Roche Healthcare Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024)
11.14.5 Roche Healthcare Recent Development
11.15 Sanofi S.A.
11.15.1 Sanofi S.A. Company Detail
11.15.2 Sanofi S.A. Business Overview
11.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Introduction
11.15.4 Sanofi S.A. Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024)
11.15.5 Sanofi S.A. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables

List of Tables
Table 1. Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Xofigo (radium Ra 223 dichloride)
Table 3. Key Players of Jevtana (cabazitaxel)
Table 4. Key Players of Inlyta (axitinib)
Table 5. Key Players of Votrient (pazopanib hydrochloride)
Table 6. Key Players of Sutent (sunitinib malate)
Table 7. Key Players of Zytiga (abiraterone acetate)
Table 8. Key Players of Xtandi (enzalutamide)
Table 9. Key Players of Opdivo (nivolumab)
Table 10. Key Players of Provenge (sipuleucel-T)
Table 11. Global Urological Cancer Therapeutics Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 12. Global Urological Cancer Therapeutics Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 13. Global Urological Cancer Therapeutics Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 14. Global Urological Cancer Therapeutics Drugs Market Share by Region (2019-2024)
Table 15. Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 16. Global Urological Cancer Therapeutics Drugs Market Share by Region (2025-2030)
Table 17. Urological Cancer Therapeutics Drugs Market Trends
Table 18. Urological Cancer Therapeutics Drugs Market Drivers
Table 19. Urological Cancer Therapeutics Drugs Market Challenges
Table 20. Urological Cancer Therapeutics Drugs Market Restraints
Table 21. Global Urological Cancer Therapeutics Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 22. Global Urological Cancer Therapeutics Drugs Market Share by Players (2019-2024)
Table 23. Global Top Urological Cancer Therapeutics Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2023)
Table 24. Ranking of Global Top Urological Cancer Therapeutics Drugs Companies by Revenue (US$ Million) in 2023
Table 25. Global 5 Largest Players Market Share by Urological Cancer Therapeutics Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Urological Cancer Therapeutics Drugs Product Solution and Service
Table 28. Date of Enter into Urological Cancer Therapeutics Drugs Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Urological Cancer Therapeutics Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 31. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2019-2024)
Table 32. Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 33. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2025-2030)
Table 34. Global Urological Cancer Therapeutics Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 35. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2019-2024)
Table 36. Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 37. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2025-2030)
Table 38. North America Urological Cancer Therapeutics Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. North America Urological Cancer Therapeutics Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 40. North America Urological Cancer Therapeutics Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 41. Europe Urological Cancer Therapeutics Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Europe Urological Cancer Therapeutics Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 43. Europe Urological Cancer Therapeutics Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 44. Asia-Pacific Urological Cancer Therapeutics Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 45. Asia-Pacific Urological Cancer Therapeutics Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 46. Asia-Pacific Urological Cancer Therapeutics Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 47. Latin America Urological Cancer Therapeutics Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Latin America Urological Cancer Therapeutics Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 49. Latin America Urological Cancer Therapeutics Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 50. Middle East & Africa Urological Cancer Therapeutics Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 51. Middle East & Africa Urological Cancer Therapeutics Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 52. Middle East & Africa Urological Cancer Therapeutics Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 53. Novartis Company Detail
Table 54. Novartis Business Overview
Table 55. Novartis Urological Cancer Therapeutics Drugs Product
Table 56. Novartis Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024) & (US$ Million)
Table 57. Novartis Recent Development
Table 58. Pfizer Company Detail
Table 59. Pfizer Business Overview
Table 60. Pfizer Urological Cancer Therapeutics Drugs Product
Table 61. Pfizer Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024) & (US$ Million)
Table 62. Pfizer Recent Development
Table 63. Johnson & Johnson Company Detail
Table 64. Johnson & Johnson Business Overview
Table 65. Johnson & Johnson Urological Cancer Therapeutics Drugs Product
Table 66. Johnson & Johnson Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024) & (US$ Million)
Table 67. Johnson & Johnson Recent Development
Table 68. AstraZeneca Company Detail
Table 69. AstraZeneca Business Overview
Table 70. AstraZeneca Urological Cancer Therapeutics Drugs Product
Table 71. AstraZeneca Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024) & (US$ Million)
Table 72. AstraZeneca Recent Development
Table 73. Astellas Company Detail
Table 74. Astellas Business Overview
Table 75. Astellas Urological Cancer Therapeutics Drugs Product
Table 76. Astellas Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024) & (US$ Million)
Table 77. Astellas Recent Development
Table 78. Bristol-Myers Squibb Company Detail
Table 79. Bristol-Myers Squibb Business Overview
Table 80. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Product
Table 81. Bristol-Myers Squibb Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024) & (US$ Million)
Table 82. Bristol-Myers Squibb Recent Development
Table 83. Abbott Laboratories Company Detail
Table 84. Abbott Laboratories Business Overview
Table 85. Abbott Laboratories Urological Cancer Therapeutics Drugs Product
Table 86. Abbott Laboratories Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024) & (US$ Million)
Table 87. Abbott Laboratories Recent Development
Table 88. Celgene Corporation Company Detail
Table 89. Celgene Corporation Business Overview
Table 90. Celgene Corporation Urological Cancer Therapeutics Drugs Product
Table 91. Celgene Corporation Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024) & (US$ Million)
Table 92. Celgene Corporation Recent Development
Table 93. Dendreon Corporation Company Detail
Table 94. Dendreon Corporation Business Overview
Table 95. Dendreon Corporation Urological Cancer Therapeutics Drugs Product
Table 96. Dendreon Corporation Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024) & (US$ Million)
Table 97. Dendreon Corporation Recent Development
Table 98. Ferring Pharmaceuticals Company Detail
Table 99. Ferring Pharmaceuticals Business Overview
Table 100. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Product
Table 101. Ferring Pharmaceuticals Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024) & (US$ Million)
Table 102. Ferring Pharmaceuticals Recent Development
Table 103. GlaxoSmithKline plc Company Detail
Table 104. GlaxoSmithKline plc Business Overview
Table 105. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Product
Table 106. GlaxoSmithKline plc Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024) & (US$ Million)
Table 107. GlaxoSmithKline plc Recent Development
Table 108. Indevus Pharmaceuticals Inc Company Detail
Table 109. Indevus Pharmaceuticals Inc Business Overview
Table 110. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Product
Table 111. Indevus Pharmaceuticals Inc Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024) & (US$ Million)
Table 112. Indevus Pharmaceuticals Inc Recent Development
Table 113. Ipsen Company Detail
Table 114. Ipsen Business Overview
Table 115. Ipsen Urological Cancer Therapeutics Drugs Product
Table 116. Ipsen Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024) & (US$ Million)
Table 117. Ipsen Recent Development
Table 118. Roche Healthcare Company Detail
Table 119. Roche Healthcare Business Overview
Table 120. Roche Healthcare Urological Cancer Therapeutics Drugs Product
Table 121. Roche Healthcare Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024) & (US$ Million)
Table 122. Roche Healthcare Recent Development
Table 123. Sanofi S.A. Company Detail
Table 124. Sanofi S.A. Business Overview
Table 125. Sanofi S.A. Urological Cancer Therapeutics Drugs Product
Table 126. Sanofi S.A. Revenue in Urological Cancer Therapeutics Drugs Business (2019-2024) & (US$ Million)
Table 127. Sanofi S.A. Recent Development
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Urological Cancer Therapeutics Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Urological Cancer Therapeutics Drugs Market Share by Type: 2023 VS 2030
Figure 3. Xofigo (radium Ra 223 dichloride) Features
Figure 4. Jevtana (cabazitaxel) Features
Figure 5. Inlyta (axitinib) Features
Figure 6. Votrient (pazopanib hydrochloride) Features
Figure 7. Sutent (sunitinib malate) Features
Figure 8. Zytiga (abiraterone acetate) Features
Figure 9. Xtandi (enzalutamide) Features
Figure 10. Opdivo (nivolumab) Features
Figure 11. Provenge (sipuleucel-T) Features
Figure 12. Global Urological Cancer Therapeutics Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 13. Global Urological Cancer Therapeutics Drugs Market Share by Application: 2023 VS 2030
Figure 14. Hospital Case Studies
Figure 15. Medical Research Laboratory Case Studies
Figure 16. Others Case Studies
Figure 17. Urological Cancer Therapeutics Drugs Report Years Considered
Figure 18. Global Urological Cancer Therapeutics Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 19. Global Urological Cancer Therapeutics Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 20. Global Urological Cancer Therapeutics Drugs Market Share by Region: 2023 VS 2030
Figure 21. Global Urological Cancer Therapeutics Drugs Market Share by Players in 2023
Figure 22. Global Top Urological Cancer Therapeutics Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2023)
Figure 23. The Top 10 and 5 Players Market Share by Urological Cancer Therapeutics Drugs Revenue in 2023
Figure 24. North America Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. North America Urological Cancer Therapeutics Drugs Market Share by Country (2019-2030)
Figure 26. United States Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Canada Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Europe Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Europe Urological Cancer Therapeutics Drugs Market Share by Country (2019-2030)
Figure 30. Germany Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. France Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. U.K. Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Italy Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Russia Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Nordic Countries Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Asia-Pacific Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Asia-Pacific Urological Cancer Therapeutics Drugs Market Share by Region (2019-2030)
Figure 38. China Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Japan Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. South Korea Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Southeast Asia Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. India Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Australia Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Latin America Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Latin America Urological Cancer Therapeutics Drugs Market Share by Country (2019-2030)
Figure 46. Mexico Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Brazil Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Urological Cancer Therapeutics Drugs Market Share by Country (2019-2030)
Figure 50. Turkey Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Urological Cancer Therapeutics Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Novartis Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2019-2024)
Figure 53. Pfizer Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2019-2024)
Figure 54. Johnson & Johnson Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2019-2024)
Figure 55. AstraZeneca Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2019-2024)
Figure 56. Astellas Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2019-2024)
Figure 57. Bristol-Myers Squibb Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2019-2024)
Figure 58. Abbott Laboratories Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2019-2024)
Figure 59. Celgene Corporation Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2019-2024)
Figure 60. Dendreon Corporation Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2019-2024)
Figure 61. Ferring Pharmaceuticals Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2019-2024)
Figure 62. GlaxoSmithKline plc Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2019-2024)
Figure 63. Indevus Pharmaceuticals Inc Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2019-2024)
Figure 64. Ipsen Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2019-2024)
Figure 65. Roche Healthcare Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2019-2024)
Figure 66. Sanofi S.A. Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2019-2024)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock